evipedia.ai ← Back to Review

Audit: QRS - Quercetin for Health & Longevity

Audit conducted on 10/08/2026 11:37 using AI4L / Opus 5

Iterations

Summary

Items Count
Total 91
Passed 81
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Spot-checked every populated span against the ER: protocol doses (ER 460–464), time-to-effect windows (ER 515), all 11 monitoring rows (ER 543–553), cadence (ER 539), 6 qualitative markers (ER 557–562), contraindications (ER 430), interactions (ER 406–428), benefit/risk tier items (ER 168–382).
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 No ER empty-state or hedged phrasing was reworded; hedged items are carried in the ER’s own Speculative/Low tiers.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Population-restricting qualifiers are retained where removal would strengthen (“in fitter adults over 40”, “in combination protocols”, “in people with high senescent cell burden”).
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Gates come only from ER Key Interactions & Contraindications; risks only from Potential Risks & Side Effects; no Benefit- or Risk-Modifying Factor is surfaced.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PMIDs, author names or NCT IDs anywhere; the single brand name “Paxlovid” matches ER 412.
1.6 The QRS does not introduce new attributions. 🟢 No attributions of any kind in the QRS.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Register matches; At-A-Glance mirrors the ER Conclusion’s own wording (ER 590–594).
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Neutral, evidence-first framing with actionable protocol and monitoring detail.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Content is presented as observed practice and trial parameters, not instruction.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No “should”, “must”, “recommend”, or “advise” anywhere in the file.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 All cells are descriptive noun phrases or statements of what trials used.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person pronouns present.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms are expanded on first use in the Monitoring table (eGFR, hsCRP, ALT, TSH, ApoB, HbA1c).
2.8 Information is presented in a concise and very compact manner 🟢 Every gate and tier item is a single short clause; trailing ER rationale is stripped.
2.9 It DOES NOT address the reader directly 🟢 Confirmed by search for you/your across the document.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Functional-optimum monitoring targets and dose thresholds are pitched at this audience.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Enhanced-absorption and intermittent senolytic protocols, plus an 11-marker laboratory panel, assume this.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 No general-population framing or simplified “ask your doctor” register.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 At-A-Glance states the effect is small and dose-gated, and that longevity claims depend on the prescription pairing.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 “Longevity” used in title and At-A-Glance; no occurrence of “anti-aging”.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 Clinical terms throughout; the plainer At-A-Glance wording is the ER Conclusion’s own (ER 594) and is required by item 7.4.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All headings, gate heads, tier labels and column headers are byte-identical to the template.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 73 anchors present; the generic marker_#* and qualitative_item# rows are expanded to 11 and 6 respectively, with no name missing.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 A structural diff against the template shows changes only inside addressed variable spans; the website=”evidence_review”, website=”audit” and website=”full_review” spans are untouched.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section used by the QRS is empty.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels and all six Qualitative Assessment bold labels are verbatim from ER 460–464 and ER 557–562.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 All 11 monitoring marker names are verbatim from the ER biomarker table.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji characters in the file; the ER’s tier and ⚠️ markers were dropped.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 The template’s single-sheet structure is intact; each section is condensed to one-line entries rather than expanded, and no markup was added beyond the required table rows and list items.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Single comment at lines 2–14, immediately after the doctype.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening “—” at line 3, closing “—” at line 13; the descriptive line 2 precedes the block.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; no metadata value is echoed on the page except the intended header date and model.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration: "00:03" is quoted, which is required by its colon.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 Line 4: er_filename: quercetin_2026-0810-0719_Opus_ER.md.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 Line 5: qrs_prompt_version: 26.7.02, matching QRS.md.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 Line 6: qrs_creation_date: 2026-0810-1043.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 Line 7: qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 “Opus” is a single word with no version or qualifier.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 Line 8: qrs_creator_ai_fullname: Opus 5.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 5” = nickname plus version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 Line 9 matches the file’s own name on disk.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 All nine values are trimmed and unquoted except the colon-bearing duration.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 Line 22: “Quercetin for Health & Longevity - Quick Reference Sheet”.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 Line 417: “Quercetin for Health & Longevity”, matching ER frontmatter line 8.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 Line 421: “08/10/2026” from creation date 2026-0810-1043.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Line 425: “Opus 5”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header contains only the title and the template subline; the ER’s “Also known as” list was not carried over.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Compresses all three Conclusion paragraphs (ER 590–594) into effect, dose gate, longevity caveat and hazards.
7.2 [at_a_glance] is no longer than 60 words 🟢 Exactly 60 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Dose/duration gate from ER 590; senolytic pairing and quercetin-alone caveat from ER 592; the three hazards from ER 594.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No acronyms; “a marker of inflammation”, “drug-processing interference”, “underdosed products” replace the technical terms.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial names, years, sample sizes or p-values.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 Only “a small, repeatable drop”; the sole figure is a dose threshold, not an effect size.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All seven items come from the “Populations who should avoid quercetin” bullet (ER 430).
8.2 [stop_items] represent the Contraindications from the ER 🟢 All seven ER avoidance populations are present, none added.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Seven <li> elements at lines 542–548.
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Rationales such as “no human safety data”, “given the estrogen-dependent tumor promotion signal in animals” and “for whom no dosing or safety data exist” are stripped; no dashes remain.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Stage 3b, the eGFR <45 mL/min/1.73 m² threshold, “active or in remission”, and the fourteen-day surgical window are all retained.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation inside parentheses in this section.
8.7 If no [stop_items] are present the section is left empty N/A Seven stop_items are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All twelve items map one-to-one to the ER’s twelve interaction bullets (ER 406–428).
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Every ER interaction bullet is represented; the ER’s separate avoidance bullet is not duplicated here.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Twelve <li> elements at lines 556–567.
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 ER severity tags (“— absolute caution”, “— caution, direction uncertain”, “— monitor”) and all consequence/mitigation sentences are stripped.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Every bullet keeps a named example list, trimmed where the ER’s was long (CYP3A4, P-glycoprotein, antihypertensives, supplement stacks).
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation inside parentheses in this section.
9.7 If no [caution_items] are present the section is left empty N/A Twelve caution_items are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Drawn from the ER Therapeutic Protocol section (ER 460–464).
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 The ER’s three named regimens — standard daily, enhanced-absorption, intermittent senolytic — are the first three bullets of the section.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER supplies three or more distinct actionable aspects; all three sets are used.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All nine cells populated; labels verbatim, values and subs traceable to ER 460, 462 and 464.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Blood pressure/CRP, exercise recovery and allergy relief, all from the ER “Time to effect” bullet (ER 515).
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 High-tier blood pressure/CRP first, then the two Medium-tier benefits in ER order; the Low-tier glucose window is correctly omitted.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER supplies more than three time-to-effect aspects; all three sets are used.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 All nine cells populated; “4–12 weeks”, “Within 7 days” and “1–4 weeks” match ER 515.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides a dedicated time-to-effect bullet, so the section is retained.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 All eighteen items map to the ER’s eighteen benefit headings (ER 168–274) in ER order.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present and populated at lines 521–532; tier assignment matches the ER exactly (2 / 4 / 8 / 4).
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Magnitude paragraphs are dropped entirely; redundant heading qualifiers (“with Sustained Higher Dosing”, “with Longer Use”, “in the High-Normal Range”, “in Fatty Liver Disease”) are stripped.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses remain in any benefits tier.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four tiers contain items in the ER.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 All thirteen items map to the ER’s thirteen risk headings (ER 304–382) in ER order.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present and populated at lines 579–590; tier assignment matches the ER exactly (2 / 2 / 6 / 3).
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Magnitude paragraphs dropped; heading tails such as “with Oral Dosing”, “at High Tissue Concentrations” and “Through Antioxidant Interference” are stripped.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses remain in any risks tier.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four tiers contain items in the ER.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Rows taken from the ER Monitoring Protocol & Defining Success biomarker table (ER 541–553).
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All 11 ER biomarker rows are present in ER order, with names and optimal ranges verbatim.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Line 731 condenses ER 539 including the twice-weekly, twelve-week, six-to-twelve-month and three-month thyroid intervals.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Taken from the qualitative marker list in ER 557–562.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All six ER qualitative markers present in ER order with bold labels verbatim.

Issues 10/08/2026 11:37

Pass rate 100.00%. No issues found.

Issues 10/08/2026 11:30

  1. 1.1 — Monitoring cadence threshold drift: [monitoring_cadence] (QRS line 731) narrows the six-month laboratory interval to doses “above 1,000 mg per day”, whereas the ER (line 539) sets it at “doses of 1,000 mg per day or above” — excluding exactly the 1,000 mg/day chronic cap the ER itself recommends (ER line 437).

Fixes 10/08/2026 11:30

  1. 1.1 — Monitoring cadence threshold drift: Changed [monitoring_cadence] from “at six months above 1,000 mg per day or with reduced kidney function” to “at six months at 1,000 mg per day or above, or with reduced kidney function”, restoring the ER’s inclusive threshold.

Issues 10/08/2026 11:22

  1. 4.5 — Sheet exceeds one A4 page: Several sections carry more than their per-section budget — the Key Interactions gate at lines 555–568 renders roughly 26 wrapped lines, and the longest Monitoring “Why” cells and Protocol sub-lines add further overflow past a single A4 page.
  2. 9.4 — Caution items not maximally concise: The CYP3A4 item lists seven drugs (line 558), the additive blood-pressure item seven supplements (line 564), and the antiplatelet item six (line 565), where three representative examples each would carry the same decision value.

Fixes 10/08/2026 11:22

  1. 9.4 / 4.5 — Caution drug lists trimmed: Shortened the over-long parentheticals in Key Interactions — CYP3A4 substrates from seven drugs to four, P-glycoprotein substrates from four to three, additive blood-pressure supplements from seven to three, antiplatelet supplements from six to three, and other supplement interactions from five to four.
  2. 4.5 — Monitoring “Why” cells condensed: Tightened the five longest rationale strings (eGFR, ALT, fasting insulin, lipid panel, ferritin) without changing the ER-supported meaning, e.g. “Gates the entire intervention; the kidney is the only organ with documented quercetin toxicity” to “Gates the intervention; the only organ with documented quercetin toxicity”.
  3. 4.5 — Protocol sub-lines shortened: Trimmed the standard and enhanced-absorption sub-lines, dropping redundant words such as “trial duration” to “duration” and “Phospholipid- or cyclodextrin-complexed formulation” to “Phospholipid- or cyclodextrin-complexed”.

Issues 10/08/2026 11:14

  1. 4.2 / 4.3 — Key Interactions labels paraphrased: Two caution_items invert the ER’s bold labels instead of using them verbatim — QRS line 564 “Additive blood-pressure-lowering supplements” for ER line 422 “Supplements with additive blood-pressure-lowering effects”, and QRS line 565 “Additive antiplatelet or anticoagulant supplements” for ER line 424 “Supplements with additive antiplatelet or anticoagulant effects”.

Fixes 10/08/2026 11:14

  1. 4.2 / 4.3 — Key Interactions labels restored verbatim: Replaced the two paraphrased caution_items labels with the ER’s own bold labels — “Additive blood-pressure-lowering supplements” → “Supplements with additive blood-pressure-lowering effects” and “Additive antiplatelet or anticoagulant supplements” → “Supplements with additive antiplatelet or anticoagulant effects” (QRS lines 564–565); the parenthetical drug lists were left unchanged.

Issues 10/08/2026 11:08

  1. 4.5 — Sheet exceeds one A4 page: Several fields carry ER elaboration past the per-section budget — the three action_#_sub cells (lines 450, 461, 472), the parenthetical lists in caution_items 9, 10 and 12 (lines 564–567), the trailing clauses in time_2_sub/time_3_sub (lines 500, 511), and the explanatory tails in qualitative_item_1/qualitative_item_4 (lines 740, 749).

Fixes 10/08/2026 11:08

  1. 4.5 — Protocol sub-cells condensed: Trimmed all three action_#_sub cells — “500 mg per day is the threshold below which blood pressure and inflammatory effects disappear” to “Effects disappear below 500 mg per day”, “bioavailability gains over plain aglycone … cost per day is considerably higher” to “bioavailability gains … cost is higher”, and “Taken with dasatinib 100 mg … Requires a prescription for dasatinib” to “With dasatinib 100 mg … Dasatinib requires a prescription”.
  2. 4.5 — Time-to-effect sub-cells trimmed: Reduced time_2_sub to “Requires consistent dosing, not a single pre-session dose.” and shortened time_3_sub to end at “a realistic overall window.”
  3. 4.5 — Key Interactions parentheticals shortened: Recast items 9 and 10 as “Additive blood-pressure-lowering supplements (…)” and “Additive antiplatelet or anticoagulant supplements (…)”, dropped “beetroot or dietary” before “nitrate”, and reduced item 12 to “(radioiodine scans, thyroid testing, chemotherapy, radiotherapy)”. All named drugs and supplements retained.
  4. 4.5 — Qualitative and cadence tails cut: Shortened qualitative_item_1 to “scored weekly 0–10 during allergy season”, removed the trailing “and the theoretical catecholamine effect” from qualitative_item_4, and compressed the cadence clause to “at six months above 1,000 mg per day or with reduced kidney function”.

Issues 10/08/2026 11:01

  1. 1.3 — Inflammation claim strengthened: [at_a_glance] (QRS line 433) states “a small, repeatable drop in blood pressure and inflammation”, whereas the ER Conclusion (ER line 590) says “a drop in blood pressure and in a common blood marker of low-grade inflammation” and the ER benefit entry (ER line 178) explicitly limits it to “a shift within the low-risk range rather than resolution of a clinically inflamed state”.

Fixes 10/08/2026 11:01

  1. 1.3 — Inflammation claim restored to ER wording: [at_a_glance] changed from “a small, repeatable drop in blood pressure and inflammation” to “a small, repeatable drop in blood pressure and in a marker of inflammation”, matching the ER Conclusion’s “a common blood marker of low-grade inflammation”; the section remains within the 60-word budget (60 words).

Issues 10/08/2026 10:50

  1. 4.5 — Content exceeds one A4 page: The Key Interactions gate (lines 556–567), the eight-entry benefits_low run (line 528), the eleven-row Monitoring table with its four-sentence cadence paragraph (lines 606–731) and risks_low (line 586) together overflow the one-page budget; no per-section condensation was applied.
  2. 12.3 — Qualifiers retained in benefits: benefits_low (line 528) keeps “with sustained higher dosing”, “in physically fit middle-aged adults”, “with longer use” and “in the high-normal range”, and benefits_medium (line 525) keeps “in combination protocols” and “in fatty liver disease”, contrary to the tier-encodes-strength rule.
  3. 13.3 — Qualifiers and mechanism retained in risks: risks_low (line 586) keeps “with oral dosing” and “around surgery and alongside antiplatelet agents”, and risks_speculative (line 589) keeps the mechanistic tails “at high tissue concentrations” and “through antioxidant interference”.
  4. 11.4 — Time-to-effect subs not standalone: time_2_sub (line 500) is the dangling fragment “Of consistent dosing.”, and time_3_sub (line 511) carries a general twelve-week evaluation window rather than content specific to the allergy label above it.

Fixes 10/08/2026 10:50

  1. 12.3 — Benefit qualifiers stripped: Removed the dosing and duration qualifiers from benefits_low (“with sustained higher dosing”, “with longer use”, “in the high-normal range”) and from benefits_medium (“in fatty liver disease”), and condensed “in physically fit middle-aged adults” to “in fitter adults over 40”. Population restrictions that carry the claim (combination protocols, rheumatoid arthritis) were retained so the ER claim is not strengthened.
  2. 13.3 — Risk qualifiers and mechanism stripped: Removed “with oral dosing” and “and alongside antiplatelet agents” from risks_low, and “at high tissue concentrations” and “through antioxidant interference” from risks_speculative. “In combination senolytic protocols” was kept in risks_medium because dropping it would misattribute the risk to quercetin alone.
  3. 11.4 — Time-to-effect subs made standalone: Replaced the dangling time_2_sub fragment “Of consistent dosing.” with “Faster than the cardiovascular endpoints; requires consistent dosing rather than a single pre-session dose.”, and retargeted time_3_sub to the allergy finding (“Measured with an enhanced-absorption formulation; twelve weeks is a realistic overall evaluation window.”).
  4. 4.5 — Condensed to the one-page budget: Tightened monitoring_cadence, marker_10_why, action_1_sub, action_2_sub and all six Qualitative Assessment entries, alongside the benefit and risk trims above, removing roughly 400 characters of body text without dropping any biomarker, gate item, benefit or risk.